Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Deferred Tax Liability (2017 - 2025)

Historic Non-Current Deferred Tax Liability for Avalo Therapeutics (AVTX) over the last 9 years, with Q3 2025 value amounting to $304000.0.

  • Avalo Therapeutics' Non-Current Deferred Tax Liability rose 9740.26% to $304000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $304000.0, marking a year-over-year increase of 9740.26%. This contributed to the annual value of $270000.0 for FY2024, which is 7419.35% up from last year.
  • According to the latest figures from Q3 2025, Avalo Therapeutics' Non-Current Deferred Tax Liability is $304000.0, which was up 9740.26% from $293000.0 recorded in Q2 2025.
  • Over the past 5 years, Avalo Therapeutics' Non-Current Deferred Tax Liability peaked at $304000.0 during Q3 2025, and registered a low of $111000.0 during Q1 2021.
  • In the last 5 years, Avalo Therapeutics' Non-Current Deferred Tax Liability had a median value of $154000.0 in 2024 and averaged $171157.9.
  • Per our database at Business Quant, Avalo Therapeutics' Non-Current Deferred Tax Liability plummeted by 609.76% in 2024 and then soared by 9740.26% in 2025.
  • Avalo Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $113000.0 in 2021, then increased by 24.78% to $141000.0 in 2022, then increased by 9.93% to $155000.0 in 2023, then surged by 74.19% to $270000.0 in 2024, then increased by 12.59% to $304000.0 in 2025.
  • Its last three reported values are $304000.0 in Q3 2025, $293000.0 for Q2 2025, and $278000.0 during Q1 2025.